Your browser is no longer supported. Please, upgrade your browser.
OMER Omeros Corporation daily Stock Chart
OMER [NASD]
Omeros Corporation
Index- P/E- EPS (ttm)-1.74 Insider Own0.50% Shs Outstand54.30M Perf Week0.74%
Market Cap780.46M Forward P/E- EPS next Y-1.44 Insider Trans-5.41% Shs Float51.57M Perf Month-9.21%
Income-89.20M PEG- EPS next Q-0.53 Inst Own58.10% Short Float21.60% Perf Quarter24.94%
Sales113.60M P/S6.87 EPS this Y34.60% Inst Trans13.40% Short Ratio12.75 Perf Half Y3.84%
Book/sh-2.43 P/B- EPS next Y1.30% ROA-81.80% Target Price- Perf Year-19.26%
Cash/sh1.03 P/C14.45 EPS next 5Y- ROE69.80% 52W Range8.50 - 20.92 Perf YTD5.61%
Dividend- P/FCF- EPS past 5Y5.10% ROI-121.90% 52W High-28.87% Beta1.93
Dividend %- Quick Ratio1.50 Sales past 5Y190.70% Gross Margin99.10% 52W Low75.06% ATR0.94
Employees258 Current Ratio1.50 Sales Q/Q7.80% Oper. Margin-59.70% RSI (14)48.97 Volatility5.05% 5.99%
OptionableYes Debt/Eq- EPS Q/Q-7.60% Profit Margin-78.50% Rel Volume0.44 Prev Close15.15
ShortableYes LT Debt/Eq- EarningsMay 11 AMC Payout- Avg Volume873.91K Price14.88
Recom2.20 SMA20-3.48% SMA505.15% SMA200-0.42% Volume383,310 Change-1.78%
May-06-19Initiated Cantor Fitzgerald Overweight $26
Jul-12-18Initiated Seaport Global Securities Buy $30
Mar-23-18Downgrade Wedbush Outperform → Neutral $47 → $19
Mar-05-18Downgrade Needham Buy → Hold
Nov-08-17Initiated H.C. Wainwright Buy $30
May-11-17Downgrade Cantor Fitzgerald Buy → Neutral $21 → $15
Mar-17-17Reiterated Needham Buy $24 → $22
Mar-17-17Reiterated Maxim Group Buy $19 → $22
Nov-16-16Reiterated Wedbush Outperform $56 → $47
Nov-10-16Reiterated Needham Buy $28 → $24
Aug-10-16Reiterated Maxim Group Buy $30 → $19
Jun-03-16Initiated Cantor Fitzgerald Buy $21
Mar-02-16Reiterated Needham Buy $30 → $28
Feb-29-16Reiterated Wedbush Outperform $65 → $62
Nov-11-15Reiterated Needham Buy $32 → $30
Aug-18-15Reiterated WBB Securities Strong Buy $60 → $75
Aug-10-15Initiated ROTH Capital Buy $38
Mar-18-15Reiterated Needham Buy $22 → $32
Feb-20-15Reiterated Maxim Group Buy $28 → $30
Feb-18-15Reiterated MLV & Co Buy $19 → $38
May-28-20 06:37AM  Edited Transcript of OMER earnings conference call or presentation 11-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-26-20 06:45PM  Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75 Investor's Business Daily
May-14-20 09:00AM  Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress Business Wire
May-12-20 06:01AM  Omeros (OMER) Q1 2020 Earnings Call Transcript Motley Fool -11.60%
May-11-20 06:55PM  Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates Zacks +6.15%
04:02PM  Omeros Corporation Reports First Quarter 2020 Financial Results Business Wire
May-08-20 08:36AM  Should You Buy Omeros (OMER) Ahead of Earnings? Zacks
May-05-20 07:00AM  Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020 Business Wire
Mar-11-20 03:38PM  Edited Transcript of OMER earnings conference call or presentation 2-Mar-20 9:30pm GMT Thomson Reuters StreetEvents -8.74%
Mar-04-20 10:00AM  Company News for Mar 4, 2020 Zacks
Mar-02-20 05:35PM  Omeros (OMER) Reports Q4 Loss, Tops Revenue Estimates Zacks +5.71%
04:03PM  Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results Business Wire
04:01PM  Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA Business Wire
Feb-24-20 07:00AM  Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020 Business Wire
Feb-11-20 09:35AM  Is Omeros Corporation's (NASDAQ:OMER) CEO Salary Justified? Simply Wall St.
08:30AM  Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors Business Wire
Feb-03-20 03:49PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
Jan-23-20 05:30PM  Omeros seeks accelerated approval from FDA for new drug American City Business Journals
Dec-20-19 05:16PM  Hedge Funds Arent Crazy About Omeros Corporation (OMER) Anymore Insider Monkey
Dec-18-19 08:30AM  myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab Business Wire
Dec-16-19 08:30AM  Omeros Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors Business Wire
Dec-13-19 09:30AM  Omeros Announces Full Exercise and Closing of Underwriters Option to Purchase Additional Shares Business Wire
Dec-10-19 08:30AM  Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva Business Wire
Dec-05-19 07:14AM  The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission Benzinga -12.66%
Dec-04-19 04:11PM  Omeros Announces Proposed Public Offering of Common Stock Business Wire +6.05%
10:42AM  Omeros Aces Late-Stage Trial Of Transplant Drug Narsoplimab Benzinga
10:38AM  Omeros stock gains on transplant drug data MarketWatch
07:00AM  Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab Business Wire
Dec-03-19 11:45PM  Edited Transcript of OMER earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-20-19 08:45AM  Omeros New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online Business Wire
Nov-19-19 08:45AM  Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston Business Wire
Nov-16-19 08:10AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
Nov-13-19 02:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
09:59AM  What Kind Of Shareholder Appears On The Omeros Corporation's (NASDAQ:OMER) Shareholder Register? Simply Wall St.
Nov-12-19 05:35PM  Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM  Omeros Corporation Reports Third Quarter 2019 Financial Results Business Wire
Nov-11-19 05:16PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
Nov-08-19 08:30AM  Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy Business Wire
Nov-07-19 05:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
08:30AM  Omeros Scientists Win 2019 Prix Galien Research Award Business Wire
Nov-06-19 08:15AM  Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019 Business Wire
Nov-04-19 03:00PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Omeros Corporation (OMER) ACCESSWIRE -16.10%
02:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
07:50AM  Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain Business Wire
Nov-01-19 11:22AM  Were Hedge Funds Right About Warming Up To Omeros Corporation (OMER)? Insider Monkey
Oct-29-19 09:00AM  Omeros Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission Business Wire
Oct-28-19 08:45AM  Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA Business Wire +6.15%
Oct-21-19 09:46AM  Here's Why You Should Hold on to Chemed (CHE) Stock Right Now Zacks
Oct-18-19 04:31AM  2 Candidates That Could Be the Next Biotech Rockets TheStreet.com
Oct-01-19 08:30AM  Product-Specific J-Code for Omeros OMIDRIA® is Now in Effect Business Wire
Sep-25-19 09:01PM  Edited Transcript of OMER earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
08:45AM  Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement Systems Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria Business Wire
Sep-16-19 08:45AM  Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction Business Wire
Sep-11-19 08:45AM  FDA Confirms Omeros Schedule for Rolling Review of the Companys BLA for Narsoplimab in the Treatment of HSCT-TMA Business Wire
Sep-10-19 10:01AM  Omeros (NASDAQ:OMER) Is Carrying A Fair Bit Of Debt Simply Wall St.
08:30AM  Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174 Business Wire
Sep-06-19 07:00AM  Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference Business Wire
Aug-22-19 10:58AM  How Medical Billing Coverage Spells Success Or Failure For Drugmakers Motley Fool
Aug-09-19 08:30AM  Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference Business Wire +11.89%
04:23AM  Omeros (OMER) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 06:20PM  Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM  Omeros Corporation Reports Second Quarter 2019 Financial Results Business Wire
Aug-05-19 04:02PM  Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019 Business Wire
Aug-01-19 10:32AM  Will Omeros (OMER) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-31-19 08:30AM  Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab Business Wire
Jul-26-19 10:33AM  The Omeros (NASDAQ:OMER) Share Price Has Gained 31% And Shareholders Are Hoping For More Simply Wall St.
Jul-24-19 08:45AM  Omeros OMIDRIA® Receives Product-Specific J-Code from CMS Business Wire
Jul-11-19 02:46PM  Calls Pop as Drug Stock Gets FDA Boost Schaeffer's Investment Research
10:23AM  Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment Benzinga
08:00AM  Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA Business Wire
Jun-14-19 11:38AM  Edited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-05-19 08:30AM  Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA Business Wire
May-29-19 12:34PM  Is Omeros Corporation's (NASDAQ:OMER) CEO Paid At A Competitive Rate? Simply Wall St.
May-15-19 07:00AM  Omeros to Present at the UBS Global Healthcare Conference Business Wire
May-11-19 03:23PM  Omeros (OMER) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 06:25PM  Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:13PM  Omeros: 1Q Earnings Snapshot Associated Press
04:02PM  Omeros Corporation Reports First Quarter 2019 Financial Results Business Wire
11:05AM  Did Hedge Funds Drop The Ball On Omeros Corporation (OMER) ? Insider Monkey
May-07-19 09:04AM  Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting Business Wire -8.78%
May-06-19 06:01PM  Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019 Business Wire
May-02-19 10:33AM  Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know Zacks
May-01-19 08:30AM  Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting Business Wire
Apr-03-19 08:30AM  Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment Business Wire
Mar-19-19 08:30AM  Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation Business Wire +5.15%
Mar-13-19 10:00AM  What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now? Zacks
Mar-02-19 11:57PM  Edited Transcript of OMER earnings conference call or presentation 1-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-01-19 07:30AM  Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results Business Wire +5.20%
Feb-26-19 07:00AM  Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019 Business Wire
Feb-22-19 07:45AM  Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences Discovering Underlying Factors of Influence GlobeNewswire
Feb-20-19 08:30AM  Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721 Business Wire +5.61%
Feb-14-19 03:40PM  Why Omeros Stock Jumped Today Motley Fool +9.63%
08:30AM  Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA Business Wire
Feb-12-19 08:30AM  Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors Business Wire
Jan-30-19 11:14AM  Can We See Significant Insider Ownership On The Omeros Corporation (NASDAQ:OMER) Share Register? Simply Wall St.
Jan-17-19 11:11AM  Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data Benzinga
08:15AM  Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy Business Wire
Jan-14-19 07:30AM  Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018 Business Wire
Jan-03-19 07:35AM  Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Dec-20-18 08:30AM  Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy Business Wire
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cable Thomas J.DirectorMay 13Option Exercise5.925,00029,60040,067May 15 08:00 PM
Cable Thomas J.DirectorMay 13Sale14.405,00071,99935,067May 15 08:00 PM
Hood Leroy E. MD PhDDirectorMar 13Option Exercise5.925,00029,60069,390Mar 17 05:25 PM
Demopulos Peter A MDDirectorDec 14Option Exercise7.563,33425,205188,516Dec 17 09:40 PM
Hood Leroy E. MD PhDDirectorDec 14Option Exercise7.5610,00075,60064,390Dec 17 09:40 PM
Cable Thomas J.DirectorDec 03Option Exercise7.5610,00075,60045,067Dec 05 09:15 PM
Cable Thomas J.DirectorDec 03Sale14.4110,000144,14835,067Dec 05 09:15 PM
Cable Thomas J.DirectorOct 14Sale15.125,00075,59035,067Oct 16 08:36 PM
Kelbon Marcia S.VP Patent and General CounselJun 07Option Exercise6.0510,00060,500210,645Jun 11 06:51 PM